----item----
version: 1
id: {CCC6228D-4A7D-4604-B86E-3AF0164C02BE}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/04/24/US quarterly results roundup
parent: {3637D24F-1472-4E41-B5A6-816481061E2D}
name: US quarterly results roundup
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 1a4d368b-be04-4f7d-bf3d-485fee2b209e

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 3

<p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 29

US quarterly results round-up
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1390

<p><pre>Guidant Revenues Net income ($ millions) ($ millions) 3 months 1995 1994 1995 1994 Vascular intervention 114.0 115.5 Cardiac rhythm management 103.9 84.6 MIS 6.9 4.0 Total 224.8 204.1 21.1 22.9 (ended March 31st)</pre><p>Of the 10% growth in net sales, unit volume accounted for 8% and favourable exchange rates for 3%, offsetting a 1% decline in average selling prices. US sales rose 7% in the quarter while international sales were up 16% against 1994's first quarter. The 1% decline in vascular intervention products is attributed to heavy stocking in Japan in January 1994. Increases in worldwide sales of tachyarrhythmia systems and international sales of Vigor pacemakers contributed to the 23% growth in cardiac rhythm management sales. R&D expenses of $33.4 million were slightly lower than those in 1994's first quarter.</p><pre><strong>[C#198601109:Hybritech]</strong> Revenues Gross profit ($ millions) ($ millions) 1995 1994* 1995 1994* 3 months 25.4 32.4 13.7 15.2 * includes Pacific Biotech (ended March 31st)</pre><p>Competition continued to affect sales of Hybritech's Tandem PSA prostate cancer test. Also contributing to lower sales and gross profits in the first quarter of 1995 was the sale of <strong>[C#198600152:Eli Lilly]</strong>'s other diagnostic business, Pacific Biotech, to Quidel in January. Lilly continues to search for a purchaser of Hybritech.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 194

{32C2DFCA-405E-43AB-88A5-3883EB932000}|{FC1DA89F-D8A0-415D-99B6-86FF397EC709}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}|{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}|{2E0CEEF8-031D-43E8-B6AA-07D1397D9E4F}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 28

US quarterly results roundup
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950424T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950424T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950424T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT052226
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 29

US quarterly results round-up
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 19

198601109,198600152
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

254101
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184117Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

1a4d368b-be04-4f7d-bf3d-485fee2b209e
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184136Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
